Recent developments in the therapy of phaeochromocytoma

Expert Opinion on Investigational Drugs

Volumn 13, Issue 12, 2004, Pages 1579-1583

  Chew, Shern L ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Adrenal; MIBG; Paraganglioma; Phaeochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXAZOSIN; ESMOLOL; GLUCAGON; HALOTHANE; ISOFLURANE; LABETALOL; METIROSINE; METOCLOPRAMIDE; NALOXONE; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; OCTREOTIDE Y 90; OPIATE; PHENOTHIAZINE DERIVATIVE; PHENOXYBENZAMINE; PRAZOSIN; PROPRANOLOL; RADIOPHARMACEUTICAL AGENT; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URAPIDIL; VINCRISTINE;

ADRENALECTOMY; ADRENERGIC RECEPTOR BLOCKING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CATECHOLAMINE SYNTHESIS; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; FOLLOW UP; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERTENSION; LAPAROSCOPIC SURGERY; MALIGNANT NEOPLASTIC DISEASE; PARAGANGLIOMA; PERIOPERATIVE PERIOD; PHEOCHROMOCYTOMA; POSTOPERATIVE CARE; PREOPERATIVE CARE; RECURRENCE RISK; REVIEW;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; CATECHOLAMINES; COMBINED MODALITY THERAPY; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 10344221539     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.12.1579     Document Type: Review

References (40)

1. COUPLAND RE: On the morphology and adrenaline-noradrenaline content of chromaffin tissue. J. Endocrinol. (1953) 9 194-203.
2. BRAVO EL, TAGLE R: Pheochromocytoma: state-of-the-art and future prospects. Endocr. Rev. (2003) 24:539-553.
3. EISENHOFER G, BORNSTEIN SR, BROUWERS FM et al.: Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat Cancer (2004) 11:423-436.
4. ROSS EJ, PRICHARD BN, KAUFMAN L, ROBERTSON AI, HARRIES BJ: Preoperative and operative management of patients with phaeochromocytoma. Br. Med. J. (1967) 28:191-198.
5. PLOUIN PF, DUCLOS JM, SOPPELSA F, BOUBLIL G, CHATELLIER G: Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J. Clin. Endocrinol. Metab. (2001) 86:1480-1486.
6. BEATTY OL, RUSSELL CF, KENNEDY L, HADDEN DR, KENNEDY TL, ATKINSON AB: Phaeochromocytoma in Northern Ireland: a 21 year review. Eur. J. Surg. (1996) 162:695-702.
7. BOUTROS AR, BRAVO EL, ZANETTIN G, STRAFFON RA: Perioperative management of 63 patients with pheochromocytoma. Cleve. Clin. J. Med. (1990) 57:613-617.
8. TAUZIN-FIN P, SESAY M, GOSSE P, BALLANGER P: Effects of perioperative α1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br. J. Anaesth. (2004) 92 512-517.
9. PROYE C, THEVENIN D, CECAT P et al.: Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery (1989) 106:1149-1154.
10. JORIS JL, HAMOIR EE, HARTSTEIN GM et al.: Hemodynamic changes and catecholamine release during laparoscopic adrenalectomy for pheochromocytoma. Anesth. Analg. (1999) 88:16-21.
11. COLSON P, RYCKWAERT F, RIBSTEIN J, MANN C, DAREAU S: Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery. Acta Anaesthesiol. Scand. (1998) 42:1114-1119.
12. BRIGGS RS, BIRTWELL AJ, POHL JE: Hypertensive response to labetalol in phaeochromocytoma. Lancet (1978) 1:1045-1046.
13. FEEK CM, EARNSHAW PM: Hypertensive response to labetalol in phaeochromocytoma. Br. Med. J. (1980) 281:387.
14. NAVARATNARAJAH M, WHITE DC: Labetalol and phaeochromocytoma. Br. J. Anaes. (1984) 56:1179.
15. RUSSELL WJ, KAINES AH, HOOPER MJ, FREWIN DB: Labetalol in the preoperative management of phaeochromocytoma. Anaesth. Intensive Care (1982) 10:160-163.
16. RUSSELL WJ, METCALFE IR, TONKIN AL, FREWIN DB: The preoperative management of phaeochromocytoma. Anaesth. Intensive Care (1998) 26:196-200.
17. SHEAVES R, CHEW SL, GROSSMAN A: The dangers of unopposed β-adrenergic blockade in phaeochromocytoma. Postgrad. Med. J. (1995) 71:58-59.
18. SAND J, SALMI J, SAARISTO J, AUVINEN O: Preoperative treatment and survival of patients with pheochromocytomas. Ann. Chir Gynaecol. (1997) 86:230-232.
19. STEINSAPIR J, CARR AA, PRISANT LM, BRANSOME ED Jr: Metyrosine and pheochromocytoma. Arch. Intern. Med. (1997) 157:901-906.
20. BRUNT LM: The positive impact of laparoscopic adrenalectomy on complications of adrenal surgery. Surg. Endosc. (2002) 16 252-257.
21. TRAINER PJ, BESSER GM: The Bart's endocrine protocols. PJ Trainer, GM Besser (Eds), Churchill Livingstone, London, UK (1995).
22. GAGNER M, LACROIX A, BOLTE E: Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. N. Engl. J. Med. (1992) 327:1033.
23. JAROSZEWSKI DE, TESSIER DJ, SCHLINKERT RT et al.: Laparoscopic adrenalectomy for pheochromocytoma. Mayo Clin. Proc. (2003) 78:1501-1504.
24. BRAUCKHOFF M, GIMM O, THANH PN et al.: Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery (2003) 134:1020-1027.
25. LAL G, DUH QY: Laparoscopic adrenalectomy-indications and technique. Surg. Oncol. (2003) 12:105-123.
26. BENTREM DJ, PAPPAS SG, AHUJA Y, MURAYAMA KM, ANGELOS P: Contemporary surgical management of pheochromocytoma. Am. J. Surg. (2002) 184:621-624.
27. CHEAH WK, CLARK OH, HORN JK, SIPERSTEIN AE, DUH QY: Laparoscopic adrenalectomy for pheochromocytoma. World J. Surg. (2002) 26:1048-1051.
28. LI ML, FITZGERALD PA, PRICE DC, NORTON JA: Iatrogenic pheochromocytomatosis: a previously unreported result of laparoscopic adrenalectomy. Surgery (2001) 130:1072-1077.
29. YIP L, LEE JE, SHAPIRO SE et al.: Surgical management of hereditary pheochromocytoma. J. Am. Coll. Surg. (2004) 198 525-534.
30. NEUMANN HP, REINCKE M, BENDER BU, ELSNER R, JANETSCHEK G: Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J. Clin. Endocrinol. Metab (1999) 84:2608-2610.
31. SAFFORD SD, COLEMAN RE, GOCKERMAN JP et al.: Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery (2003) 134 956-962.
32. EDSTROM EE, HJELM SKOG AL, HOOG A, HAMBERGER B: The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur. J. Surg. Oncol. (2003) 29:278-283.
33. 131)I-mIBG]. Clin. Endocrinol. (2001) 55:47-60.
34. LOH KC, FITZGERALD PA, MATTHAY KK, YEO PP, PRICE DC: The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J. Endocrinol Invest. (1997) 20:648-658.
35. ROSE B, MATTHAY KK, PRICE D et al.: High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer (2003) 98:239-248.
36. AVERBUCH SD, STEAKLEY CS, YOUNG RC et al.: Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann. Intern. Med. (1988) 109:267-273.
37. SISSON JC, SHAPIRO B, SHULKIN BL, URBA S, ZEMPEL S, SPAULDING S: Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am. J. Clin. Oncol. (1999) 22:364-370.
38. YOSHIDA S, HATORI M, NOSHIRO T, KIMURA N, KOKUBUN S: Twenty-six-years' survival with multiple bone metastasis of malignant pheochromocytoma. Arch Orthop. Trauma Surg. (2001) 121 598-600.
39. KERGER BD, JAMES RC, ROBERTS SM: An assay for phentolamine using high performance liquid chromatography with electrochemical detection. Anal. Biochem. (1988) 170:145-151.
40. MIHM FG, SANDHU JS, BROWN MD, ROSENTHAL MH: Short-acting β-adrenergic blockade as initial drug therapy in pheochromocytoma. Crit. Care Med. (1990) 18:673-674.